Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
Am J Hematol ; 86(1): 98-101, 2011 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-21064136

RESUMO

Subacute methotrexate neurotoxicity (MTX-NT) may occur days to weeks after systemic or intrathecal (IT) MTX administration and is often manifest by stroke-like symptoms. The pathogenesis of MTX-NT has mainly been associated with cerebral folate homeostasis, but the specific mechanism leading to the development of this complication is mostly unknown and is likely to be multifactorial. Most of studies aimed to determine putative genetic determinants of this syndrome have been focused on the methylenetetrahydrofolate reductase (MTHFR) C677T single nucleotide polymorphism (SNP). However, there are other functional polymorphisms that have also been identified in enzymes and transporters related to MTX and folate homeostasis. In this context, we carried out an extensive genetic analysis through the screening of 21 SNPs in 11 relevant genes in a five-year-old girl with acute lymphoblastic leukemia (ALL) who developed MTX-NT. The analysis revealed the presence of numerous genetic variants that may have accounted for the neurotoxicity observed. We discuss the putative role of MTX pharmacogenetics in the pathogenesis of MTX-NT.


Assuntos
Antimetabólitos Antineoplásicos/efeitos adversos , Ácido Fólico/metabolismo , Metotrexato/efeitos adversos , Síndromes Neurotóxicas/etiologia , Leucemia-Linfoma Linfoblástico de Células Precursoras/tratamento farmacológico , Leucemia-Linfoma Linfoblástico de Células Precursoras/genética , Antimetabólitos Antineoplásicos/uso terapêutico , Pré-Escolar , Feminino , Ácido Fólico/genética , Humanos , Imageamento por Ressonância Magnética , Metotrexato/uso terapêutico , Síndromes Neurotóxicas/genética , Síndromes Neurotóxicas/metabolismo , Síndromes Neurotóxicas/patologia , Polimorfismo de Nucleotídeo Único , Leucemia-Linfoma Linfoblástico de Células Precursoras/metabolismo
2.
BMC Infect Dis ; 7: 40, 2007 May 10.
Artigo em Inglês | MEDLINE | ID: mdl-17493279

RESUMO

BACKGROUND: Fusarium spp. is being isolated with increasing frequency as a pathogen in oncohematologic patients. Caspofungin and amphotericin B have been reported to have synergistic activity against Fusarium spp. CASE PRESENTATION: We herein report a case of disseminated fusariosis diagnosed by chest CT scan and positive blood cultures to Fusarium spp. Because the patient's clinical condition deteriorated, CRP levels increased, and blood cultures continued to yield Fusarium spp. despite liposomal amphotericin B monotherapy up to 5 mg/kg daily, treatment with caspofungin was added. Within 2 weeks of onset of combined antifungal therapy, the chest CT scan demonstrated a progressive resolution of the pulmonary lesions. Upon discontinuation of intravenous antifungals, the patient received suppressive therapy with oral voriconazole. Three months later, a chest CT scan showed no abnormalities. Twenty-five months after discontinuation of all antifungal therapy, the patient remains in complete remission of her neoplastic disease with no signs of clinical activity of the Fusarium infection. CONCLUSION: This is the first description of successful treatment of disseminated fusariosis in a pediatric patient with acute lymphoblastic leukemia with caspofungin and amphotericin B followed by oral suppressive therapy with voriconazole.


Assuntos
Anfotericina B/uso terapêutico , Antifúngicos/uso terapêutico , Fusarium/efeitos dos fármacos , Micoses/tratamento farmacológico , Peptídeos Cíclicos/uso terapêutico , Leucemia-Linfoma Linfoblástico de Células Precursoras/complicações , Anfotericina B/administração & dosagem , Antifúngicos/administração & dosagem , Caspofungina , Criança , Quimioterapia Combinada , Equinocandinas , Feminino , Fusarium/classificação , Humanos , Lipopeptídeos , Micoses/complicações , Micoses/microbiologia , Peptídeos Cíclicos/administração & dosagem , Pirimidinas/administração & dosagem , Pirimidinas/uso terapêutico , Resultado do Tratamento , Triazóis/administração & dosagem , Triazóis/uso terapêutico , Voriconazol
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA